Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Strs Ohio

Strs Ohio lowered its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 12.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 14,552 shares of the medical equipment provider’s stock after selling 2,127 shares during the quarter. Strs Ohio’s holdings in Zimmer Biomet were worth $1,770,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Clear Street Markets LLC purchased a new position in Zimmer Biomet during the fourth quarter worth approximately $27,000. Lazard Asset Management LLC raised its stake in Zimmer Biomet by 70.5% during the third quarter. Lazard Asset Management LLC now owns 283 shares of the medical equipment provider’s stock worth $31,000 after purchasing an additional 117 shares during the period. Dark Forest Capital Management LP purchased a new position in Zimmer Biomet during the first quarter worth approximately $35,000. Activest Wealth Management raised its stake in Zimmer Biomet by 410.4% during the fourth quarter. Activest Wealth Management now owns 342 shares of the medical equipment provider’s stock worth $42,000 after purchasing an additional 275 shares during the period. Finally, Peoples Bank KS purchased a new position in Zimmer Biomet during the third quarter worth approximately $48,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on ZBH. Raymond James increased their price target on shares of Zimmer Biomet from $133.00 to $137.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 3rd. JPMorgan Chase & Co. increased their price target on shares of Zimmer Biomet from $115.00 to $125.00 and gave the stock a “neutral” rating in a research note on Friday, February 9th. Citigroup raised their target price on shares of Zimmer Biomet from $134.00 to $140.00 and gave the company a “neutral” rating in a research note on Wednesday, April 3rd. StockNews.com downgraded shares of Zimmer Biomet from a “strong-buy” rating to a “buy” rating in a research note on Monday, February 19th. Finally, Truist Financial raised their target price on shares of Zimmer Biomet from $133.00 to $135.00 and gave the company a “hold” rating in a research note on Friday, February 9th. One analyst has rated the stock with a sell rating, nine have given a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $139.39.

Zimmer Biomet Price Performance

ZBH opened at $119.43 on Friday. The company has a fifty day simple moving average of $126.33 and a 200 day simple moving average of $119.22. The firm has a market cap of $24.54 billion, a price-to-earnings ratio of 24.42, a PEG ratio of 2.19 and a beta of 1.01. Zimmer Biomet Holdings, Inc. has a twelve month low of $102.00 and a twelve month high of $149.25. The company has a current ratio of 1.61, a quick ratio of 0.78 and a debt-to-equity ratio of 0.39.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share for the quarter, topping the consensus estimate of $2.15 by $0.05. The company had revenue of $1.94 billion during the quarter, compared to analyst estimates of $1.93 billion. Zimmer Biomet had a net margin of 13.85% and a return on equity of 12.79%. The firm’s revenue for the quarter was up 6.3% compared to the same quarter last year. During the same period last year, the business earned $1.88 EPS. Equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.07 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.80%. The ex-dividend date of this dividend is Wednesday, March 27th. Zimmer Biomet’s dividend payout ratio is currently 19.63%.

Insiders Place Their Bets

In other Zimmer Biomet news, VP Chad F. Phipps sold 26,156 shares of the firm’s stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $128.62, for a total transaction of $3,364,184.72. Following the completion of the transaction, the vice president now directly owns 44,145 shares of the company’s stock, valued at approximately $5,677,929.90. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.95% of the stock is owned by company insiders.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.